ערך בספרים למניה: Ascentage Pharma Group (AAPGV)

Compliance with environmental regulations for reagent disposal requires expenditures, as confirmed by the book value per ordinary share, where the parameter settled at 0.88. The active implementation of innovative leukemia drugs, which expands the global presence of Ascentage Pharma Group (AAPGV) through strategic alliances, helps overcome geopolitical barriers in patent law and logistics.

To protect portfolio capital, priority is given to assets with sustainable net asset growth, which is critical for Ascentage Pharma Group (AAPGV) during the period of costly clinical trials for oncology drugs. Assessing the financial cushion via book value per share allows for the measurement of residual asset value minus liabilities, reflecting capital management efficiency and the level of protection against bankruptcy.